March 24, 2017 — Facing the reality of not having enough votes to secure its passage, House leadership withdrew the ...
Safe implementation of new technologies and therapies accompany classic patient safety challenges on ECRI Institute's “2017 Top 10 Patient Safety Concerns for Healthcare Organizations.” The report highlights concerns from health information management, clinical decision support and new oral anticoagulants, to long-standing concerns like test result reporting and follow-up and unrecognized patient deterioration.
At the 2017 American College of Cardiology's Annual Scientific Session & Expo (ACC.17), Philips showcased a broad range of integrated, patient-centric solutions designed to address the prevention, diagnosis, minimally invasive treatment and chronic care at home of cardiac conditions.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Justin Davies, MBBS, of Imperial College London, and Matthias Götberg, M.D, Ph.D., of Skane University Hospital, detail ...
Bleeding complications did not increase for patients with acute coronary syndrome treated with rivaroxaban in addition to an antiplatelet medication compared with patients who received the standard treatment of aspirin plus an antiplatelet drug, according to new research. The research was presented at the American College of Cardiology’s 66th Annual Scientific Session, March 17-19 in Washington, D.C.
March 23, 2017 — Biotronik announced the European launch of the Edora series, its smallest series of pacemakers and ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low dose ...
March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic valve ...
In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of effective statin therapy, had widely varying effects on LDL cholesterol levels and had no benefit on cardiovascular events among those with LDL lower than 100 mg/dL. However, in patients at high cardiovascular risk who had baseline LDL of greater than 100 mg/dL, bococizumab significantly reduced the risk of cardiovascular events by 21 percent compared with placebo, according to research presented at the American College of Cardiology’s 66th Annual Scientific Session, March 17-19 in Washington, D.C.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
March 22, 2017 — Patients with recurrent fainting episodes (syncope) who received a pacemaker delivering a pacing ...
March 22, 2017 — Two U.S. Food and Drug Administration (FDA)-cleared embolic protection systems designed to remove ...
Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption approval from the U.S. Food and Drug Administration (FDA) to initiate a clinical trial in the U.S. for its Sierra Ligation System medical device. Aegis developed the Sierra technology in partnership with the Mayo Clinic in Rochester, Minn. Sierra could, with additional clinical research, prove to prevent stroke in patients with atrial fibrillation (AF), according to the company.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Here is a list of the American College of Cardiology (ACC) 2017 annual meeting late-breaking clinical trials presented ...
March 22, 2017 – The U.S. Food and Drug Administration (FDA) and granted market clearance to the Medtronic CoreValve ...
March 21, 2017 — Toshiba Medical demonstrated its Forward projected model-based Iterative Reconstruction SoluTion (FIRST ...